Full Press Release Details
Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U S Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities.
RYTM
Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U S Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities
Key Takeaway: Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U S Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities